Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated regions of the dark genome, describing its findings in talks and posters being presented at the Society of Immunotherapy in Cancer (SITC) meeting in National Harbor, Md., Nov. 5-9, 2025.
Acrivon Therapeutics Inc. has developed a new WEE1/PKMYT1 inhibitor, ACR-2316, to overcome the limitations observed with previous WEE1 and PKMYT1 inhibitors in the treatment of cancer.
Accutar Biotechnology Inc. recently presented preclinical data on AC-4847, a first-in-class PI3Kα-targeting degrader-antibody conjugate (DAC) designed for selective treatment of PI3Kα-driven cancers.
Montse Rosa Therapeutics Inc. has developed a molecular glue degrader named MRT-2359 that selectively degrades the translation termination factor ERF3A.
Researchers at Crossbridge Bio Inc. have conducted preclinical evaluation of CBB-120, a novel TROP2-directed dual-payload ADC designed to combine TOP1i and ATR inhibitor (ATRi) mechanisms for enhanced therapeutic efficacy.
Carbon Biosciences Inc. has presented data on a parvovirus-based vector that restores full-length cystic fibrosis transmembrane conductance regulator (CFTR) gene for treating cystic fibrosis.
Changchung Genescience Pharmaceutical Co. Ltd., reported effects of the bispecific antibody-drug conjugate (ADC) of Gensci-143, is in metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors.
Advanced gastric cancer continues to pose a significant medical challenge because of the scarcity of effective treatments and the frequent development of resistance to available drugs.
Researchers from Sionna Therapeutics Inc. presented preclinical efficacy data on first-in-class NBD1 stabilizers and their use in combination with complementary modulators to correct cystic fibrosis transmembrane conductance receptor (CFTR) assembly.
RSS
